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Abstract
Purpose Stapled transanal rectal resection (STARR) in pa-
tients with obstructive defecation syndrome (ODS) is limited
by the capacity of the circular stapler used. This prospective
cohort study was conducted to assess real-world clinical out-
comes of STARR with the new CONTOUR® TRANSTAR™
device, shortly named TRANSTAR, at 12 months
postoperatively.
Methods From January 2009 to January 2011, consecutive
patients who underwent TRANSTAR in 22 European colo-
rectal centers were enrolled in the study. Functional outcomes
and quality of life were assessed by the changes in a number of
scoring systems (Knowles-Eccersley-Scott-Symptom (KESS)
score, ODS score, St. Mark’s score, Euro Quality of Life-5
Dimension (EQ-5D) score, and Patient Assessment of Con-
stipation—Quality of Life (PAC-QoL) score), at 12 months as
The TRANSTAR Registry Study Group:
K. Frommhold1, H. Schimmelpfennig2, M. Konrad3, H. Müller-Lobeck4,
G. Aumann G5, M. El-Din6, R. Manger7, J. Kirchner8, T. Deska9, R.
Scherer10, G. Ferulano11, I. Corsale12, F. Pigot13, JJ. Tuech14, R. Villet15,
P.A. Lehur16, K. Wolff17, F. de la Portilla18, M. Alcántara Moral19, A.
D’Hoore20, M. Abrahamowicz21, J.P. Da Costa22.
1Klinikum Bochum; Germany, 2Klinik Neustadt; Germany, 3Klinikum
Neustadt; Germany, 4Alice Hospital Darmstadt; Germany, 5Klinikum
Augsburg; Germany, 6Oder-Spree Krankenhaus, Beeskow; Germany,
7Wertachklinik, Schwabmünchen; Germany, 8Diakoniekrankenhaus,
Rotenburg/Wümme; Germany, 9Marien-Hospital, Witten; Germany,
10Krankenhaus Waldfrieden, Berlin; Germany, 11A.O.U. Frederico II,
Napoli; Italy, 12Ospedale Della Valdinievole, Pescia; Italy, 13Hospital
Bagatelle, Talence Cedex; France, 14Rouen University Hospital, Rouen
Cedex; France, 15Hospital des Diaconesses, Paris; France, 16CHU des
Nantes, Nantes; France, 17Kantonsspital St. Gallen, St. Gallen; Switzer-
land, 18Hospital Juan Ramon Jimenez, Espartinas/Sevilla; Spain,
19Corporacio Santiaria Parc Tauli, Sabadell; Spain, 20UZ Leuven, Leu-
ven; Belgium, 21Krankenhaus St. Elisabeth, Wien; Austria, 22Hospital
Distrital de Santàrem, Santarèm; Portugal.
G. Ribaric
Clinical and Medical Affairs, Ethicon Endo-Surgery (Europe)
GmbH, European Surgical Institute, Norderstedt/Hamburg, Germany
A. D’Hoore
Department of Abdominal Surgery, University Hospital Leuven,
Leuven, Belgium
G. Schiffhorst
Department of Statistics and Biometry, IGES Institute GmbH, Berlin,
Germany
E. Hempel
Clinical Data Management, IGES Institute GmbH, Berlin, Germany
G. Ribaric (*)
Clinical and Medical Affairs, Ethicon Endo-Surgery (Europe)
GmbH, MD&D EMEA (Europe, Middle East, Africa), Johnson &
Johnson, Hummelsbütteler Steindamm 71, 22851 Norderstedt,
Germany
e-mail: gribaric@its.jnj.com
Int J Colorectal Dis (2014) 29:611–622
DOI 10.1007/s00384-014-1836-8
compared to baseline. All complications were recorded and
analyzed.
Results A total of 100 patients (98 % female), mean age
60 years, were entered in the study. Statistically significant
improvements were seen in the KESS (median 18 vs. 6;
p<0.01), ODS (median 15 vs. 4; p<0.01), and PAC-Qol
scores (median 2.10 vs. 0.86; p<0.01). St. Mark’s and EQ-
5D scores improved nonsignificantly. Complications were
reported in 11 % of patients, including bleeding (5 %), staple
line complications (3 %), urinary retention (2 %), and persis-
tent pain (1 %). No major complications or mortality
occurred.
Conclusion TRANSTAR facilitated a tailored, real circumfer-
ential full-thickness rectal resection, leading to improved pa-
tient functional and quality of life outcomes at 12 months
postoperatively. It represents a safe and effective treatment
for ODS in local clinical practice, although the sustainability
of real-world results needs to be proven in the long-term
follow-up.
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Background
Obstructive defecation syndrome (ODS) is a poorly understood
condition, characterized by the urge to defecate but an impaired
ability to evacuate the rectum [1, 2]. The symptoms include
frequent visits to the toilet with unsuccessful evacuation at-
tempts, prolonged straining, anorectal discomfort or pain, fresh
rectal bleeding, a sensation of incomplete evacuation, and the
need for manual assistance [2, 3]. Structural abnormalities such
as rectocele, enterocele or genital prolapse, and non-relaxing
puborectalis may be associated with ODS, or coexist [4].
However, the internal rectal mucosal prolapse and rectal intus-
susception have been recognized as major pathomorphological
determinants of ODS, and consequently, a plethora of abdom-
inal, vaginal, and laparoscopic surgical procedures have been
used to correct the underlying condition [5–8].
As a minimally invasive technique for achieving a full-
thickness resection of the distal rectum, stapled transanal
rectal resection (STARR) has been proposed for the treatment
of ODS by performing two firings of the PPH-01 circular
stapler (Ethicon Endo-Surgery, Inc., Cincinnati, OH), which
was originally designed for use in stapled hemorrhoidopexy
[9, 10]. In 2006, the National Institute for Health and Care
Excellence (NICE) in the United Kingdom issued clinical
guidance on STARR concluding that the current evidence
for its safety and efficacy for ODS did not appear adequate
for this procedure to be used without special arrangements for
consent and for audit or research [4].
In response to the NICE guidance, the European STARR
registry was established through the collaboration between the
manufacturer, Ethicon Endo-Surgery (Europe) GmbH,
Norderstedt, Germany, and the colorectal societies in France,
Germany, Italy, and the UK. The real-world outcomes from
this registry have recently been published, reinforcing the
conclusions from single- and multicenter trials that STARR
provides a significant patient benefit, at least in the short term,
and can be performed safely and without major morbidity
[11–15]. Based on the published evidence, NICE issued its
updated clinical guidance on STARR in 2010, concluding
that: “The current evidence on the safety and efficacy of
stapled transanal rectal resection (STARR) for obstructed
defecation syndrome (ODS) is adequate for this condition
which can significantly affect the quality of life. The proce-
dure may therefore be used with normal arrangements for
clinical governance, consent and audit” [5].
Despite these conclusions on its proven safety and efficacy
by the leading independent scientific institute (NICE), the
limitations of STARR, mostly related to the design of the
circular stapler used, were recognized by a broad surgical
community. During this transanal procedure, the rectal wall
resection is performed “blind” after the insertion of the circu-
lar stapler in the lower rectum, which might cause the entrap-
ment of the device in the dilator and increase the risk of rectal
perforation [2, 16]. Furthermore, the volume of resection was
dependent on the capacity of the circular stapler housing rather
than on the size of the underlying rectal intussusceptions,
without the possibility for surgeons to tailor the extent of the
rectal resection to the size of the prolapse [2, 17].
As a response to the observed difficulties, a new stapling
device, the CONTOUR® TRANSTAR™ curved cutter-
stapler (Ethicon Endo-Surgery, Inc., Cincinnati, OH), was
designed to improve STARR by allowing the tailored circum-
ferential correction of the internal rectal prolapse under con-
tinuous visual control. Following the stapler development, the
innovative transanal stapling technique STARR with CON-
TOUR® TRANSTAR™, shortly named TRANSTAR, has
been proposed for the treatment of ODS [2, 16, 17] and was
selectively launched in European countries where the health
care decision-makers explicitly recommended the broad as-
sessment of transanal stapling procedures in local clinical
practice [4, 5, 7].
A major challenge in assessing local practice reported in
the literature previously, concluded that the variation phenom-
enon is sowidespread and robust in local practice that it can be
found almost anywhere where health care researchers look for
it: between the care of the very young and the very old,
between inpatient and outpatient settings, and between several
geographic regions [18]. The aim of this study was to assess
the short-term safety and effectiveness of TRANSTAR in the
real-world clinical environment where the variation phenom-
enon exists.
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Methods
Study design and setting
This registry was designed as a prospective, real-world, mul-
ticenter cohort study to capture short-term safety, functional,
and patient-reported outcomes with the use of TRANSTAR,
taking into account the contemporary variations in local sur-
gical practice throughout Europe. The anonymous patient data
were entered in the local investigating centers according to the
study protocol and into standardized data collection forms
(clinical record forms). These were subsequently adapted
and transcribed into electronic format for web-based data
collection to allow patient data to be collected at the same
time in all centers. Aweb-based interface was used to facilitate
simultaneous data entry, concurrently merging the data into a
single European TRANSTAR Registry data set. The online
interface and data entry were monitored and managed by an
independent clinical trial and statistical support agency (CSG-
Clinische Studien Gesellschaft mbH, Berlin, Germany, and
IGES Institut GmbH, Berlin, Germany). A European steering
group was established to oversee the data collection, analysis,
and interpretation. The study was conducted in accordance
with applicable local and national laws and regulations, with
the Medical Devices Directive 93/42/EEC (MDD) Annex X,
the European Standard EN ISO 14155-1, and with the Decla-
ration of Helsinki and all its amendments. The central ethical
committee of the Board of Physicians, Berlin, Germany, ap-
proved the study, and each individual investigating center
obtained approval from its local ethical committee. The pa-
tient data collection was the responsibility of the investigating
surgeons, who certified that all patients gave written informed
consent to take part in the study. This study was registered
online in the publicly available trials database clinicaltrials.
gov as “International Multicenter Prospective Transtar
Registry” with the identification number NCT00909116.
The STROBE Statement-checklist was used to report the
results of this cohort study.
In total, 22 colorectal surgeons from Austria, Belgium,
France, Germany, Italy, Portugal, Spain, and Switzerland en-
rolled patients in the electronic database. All investigating
surgeons were experienced in the original STARR technique
and required to complete a specific training in TRANSTAR at
the manufacturer surgical education center in Norderstedt,
Germany. Following the training, the investigators’ first
TRANSTAR cases performed in the local setting were mon-
itored by the members of STARR Pioneers, a surgical expert
group created by Ethicon Endo-Surgery (Europe) GmbH,
Norderstedt, Germany, to support continuous education and
proctorship of the transanal stapling techniques for anorectal
prolapse. In this way, the investigating surgeons gained profi-
ciency with the new stapling device before starting to enroll
the patients in this study. The clinical outcomes of interest
were preoperative patient clinical status, surgical complica-
tions, postoperative functional outcomes, and quality of life
results. The longitudinal follow-up assessments were sched-
uled 6 weeks and 6 and 12 months after surgery, with the aim
to perform the analysis of the results at 12 months follow-up
as compared to baseline.
Participants
Consecutive patients with ODS treated with TRANSTAR in
the 22 investigating centers across Europe were included in
this cohort. Inclusion recommendations in the study protocol
were aligned with the recently published patient selection
algorithm for STARR [19]. Briefly, the patients were selected
for the surgery on the basis of recognized clinical symptoms of
ODS (e.g., frequent visits to the toilet with unsuccessful
evacuation attempts, prolonged straining, anorectal discom-
fort or pain, a sensation of incomplete evacuation, and the
need for manual assistance) associated with evidence of rectal
pathology such as rectocele and/or internal rectal prolapse
confirmed by clinical examination with proctoscopy and/or
diagnostic imaging (defecography or MRI). An adequate anal
sphincter function was assessed at least with a digital rectal
examination.
Exclusion criteria included patients with a contraindication
to general anesthesia, physical or psychological problems
precluding data collection, and coexisting inflammatory or
septic conditions of the rectum. Recommendations were made
surrounding preoperative investigation, patient preparation,
operative technique, and postoperative care.
However, the ultimate decision-making was left to individ-
ual investigators in line with local policy.
Surgical technique and postoperative recommendations
Recommendations for the surgical technique were based on
the recently published description of TRANSTAR [2, 16].
Briefly, the preoperative preparation included one or two
phosphate enemas the morning of surgery, routine deep vein
thrombosis prophylaxis, and perioperative broad spectrum
antibiotics. General or regional anesthesia was used based
on the individual surgeon’s preference. The patient was placed
in the lithotomy position with the hips in hyperflexion. An
initial examination was undertaken to confirm the presence
and extent of the internal rectal prolapse and rectocele, and to
confirm the absence of coexistent pathology. The CON-
TOUR® TRANSTAR™ stapling kit (Ethicon Endo-Surgery
Inc., Cincinnati, OH, USA) was opened and the circular anal
dilator (CAD) gently introduced and fixed to the perianal skin
with four cardinal sutures. A swab was inserted and gently
pulled outward to visualize the apex of the intussusception.
Finally, the TRANSTAR technique was performed in three
steps: step 1: parachute suture placement, step 2: opening of
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the prolapse, and step 3: circumferential resection. Regarding
the postoperative period, an easily digestible diet from the first
postoperative day to the end of hospitalization and adminis-
tration of analgesics as required were recommended. The
thrombotic prophylaxis was given until discharge from the
hospital.
Variables
Functional and patient-reported outcomes were measured by
using disease-specific and generic-scoring systems. The pri-
mary study endpoint was defined as the change in the validat-
ed KESS (Knowles-Eccersley-Scott-Symptom) constipation
score at 12 months postoperatively as compared to baseline
[20]. Accordingly, the secondary study endpoints were de-
fined as the change in the ODS (Longo) constipation score, St.
Mark’s (Vaizey) incontinence score, and disease-specific
PAC-QoL score (Patient Assessment of Constipation—Qual-
ity of Life), as well as the generic quality of life instruments
EQ-5D (Euro Quality of Life-5 Dimension) and EQ-5D VAS
(Visual Analog Scale), between baseline and 12 months
follow-up [15, 21–26]. Monitoring of complications started
in the hospital and was followed up in the outpatient setting
until 12 months after surgery.
Functional scores
Knowles-Eccersley-Scott-Symptom (KESS) score The KESS
score has been statistically validated as a tool for
distinguishing constipated patients with a proven pathophys-
iologic abnormality, from those in whom physiologic investi-
gations were normal, predicting 96 % of cases correctly [20].
The overall KESS score is derived by summation of its indi-
vidual components to give a maximum score of 40. A higher
score indicates more severe symptoms. There are no known
biological or physiological markers for the severity of consti-
pation, so it is unclear what the significance of an overall
KESS score is. However, in its validation report, constipated
patients with a median KESS score of 20 (range, 11–35) were
significantly different from healthy controls presenting with a
median score of 2 (range, 0–6; P<0.0001), with no overlap
between the scores of constipated and control patients [20].
Moreover, using a cut-off criterion of ≥10, the overall KESS
score had a 100 % sensitivity (95 % confidence interval (CI)=
95–100 %) and a 100 % specificity (95 % CI=63–100 %) to
differentiate clearly constipated patients from healthy controls
[20]. Accordingly, the KESS score was used as a primary
functional endpoint to monitor the clinical effectiveness of
TRANSTAR in this study.
Obstructive Defecation Score (ODS) (A. Longo) The Longo’s
ODS score is an unvalidated tool for assessing functional
symptoms of outlet obstruction which was frequently used
in previously published trials on STARR. Nine symptoms of
obstructive defecation are scored on a scale of 0 to 4, and
accordingly, the maximum ODS score is 36. The total ODS
score is derived by summation of the individual components
with a higher score indicating more severe symptoms [2, 15].
St. Mark’s incontinence score (Vaizey C.J.) St. Mark’s score is
a validated scoring system that combines components of
incontinence disorder (fecal incontinence for solid or liquid
stool or for flatus alone, as well as frequency and quantity of
stool lost), with an assessment of defecatory urgency and the
need to take antidiarrheal medication. Impaired incontinence
may be passive—that is, without the patient’s awareness, or
urgent—that is, the inability to defer defecation, and both of
these are reflected in the scale. An indication of the effect of
incontinence on lifestyle (including the need to use pads or
plugs and the ability to perform work and leisure activities) is
also taken into account in the validated St. Mark’s score [21].
The total score is derived by summation of the individual
components, giving a maximum score of 24, with a higher
score indicating worse function [21].
Quality of life instruments
Patient Assessment of Constipation Quality of Life (PAC-QoL)
score The PAC-QoL score is a comprehensive assessment of
the burden of constipation on patients’ everyday functioning
and well-being [22]. It is a validated, internally consistent,
reproducible questionnaire that was developed to evaluate
constipation over time. The 28 items of the PAC-QoL form
four subscales (worries and concerns, physical discomfort,
psychosocial discomfort, and satisfaction), as well as a total
score. The PAC-QoL scale scores are significantly associated
with abdominal pain (p<0.001) and constipation severity
(p<0.05). PAC-QoL score was assessed according to its orig-
inal derivations, with an improvement in QoL expressed by a
decrease in numerical value of the score [22]. PAC-QoL is a
disease-specific patient-reported instrument and was therefore
selected as the main measure of the TRANSTAR impact on
patients’ quality of life.
EuroQoL-5-dimensions (EQ-5D and EQ-VAS) score The EQ-
5D is a validated generic health-related quality of life assess-
ment yielding a patient health profile along five dimensions:
mobility, self-care, usual activities, pain/discomfort, and
anxiety/depression [19]. Each dimension is represented by
one item with three response options: no problem, some
problems, and severe problems. Responses to these five items
can be normatively weighted to derive an EQ-5D utility score
with a range of −0.594 to 1 (one being ultimate health). The
EQ-5D score was assessed according to its original deriva-
tions, with an improvement in QoL expressed by an increase
in numerical value of the score [23, 24]. A difference of ≥0.07
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in EQ-5D utility has been identified as clinically important
[25]. The EQ-VAS is a visual analog scale representing a
single-item global quality of life assessment in which patients
are asked to rate their current health on a scale from 0 (worst
imaginable) to 100 (best imaginable) [26]. The EQ-5D and
EQ-VAS were selected in this registry because of their useful-
ness in estimating the relative cost-effectiveness of a surgical
intervention.
Statistical methods
The completed questionnaires of the scoring systems were
analyzed comparing 12-month follow-up with baseline data.
Mean andmedian values were computed for all functional and
quality of life scoring systems and were presented along with
their 95 % CI. The collected patient data were analyzed using
SPSS 19 (Statistical Package for the Social Sciences; SPSS,
Chicago, IL, USA) software. For the comparisons between
baseline and 12 months functional and quality of life score
outcomes, the nonparametric Wilcoxon signed ranks test or t
test were used where appropriate. The chi-square test or two-
tailed Fisher exact test were used to compare qualitative data.
All p values <0.05 were considered statistically significant.
Results
Demographics and baseline findings
Between January 2009 and January 2011, a total of 100
consecutive patients with ODS who underwent TRANSTAR
in the 22 local investigating centers were enrolled in this
cohort study. The median number of patients enrolled per an
investigating center was 5 (range, 1–11). During the recruit-
ment period, 11 centers recruited up to four patients, ten
centers recruited 5–10 patients, and one center recruited 11
patients.
The majority of the patients were female (98 %). The mean
age of the cohort was 60 (range, 27–82) years, and the mean
body mass index (BMI) 27 (range, 18–45) kg/m2. Of these
patients, 41 % were healthy, 45 % had mild systemic disease,
14 % had severe systemic disease, and no patients had severe
systematic disease that was a constant threat to life. Previous
abdominal surgery included hysterectomy in 32 %,
hemorrhoidectomy in 13 %, and pelvic floor repair in 12 %
of the cohort.
Prior to surgery for ODS, all 100 (100 %) patients
underwent clinical anorectal examination and proctoscopy in
the investigating centers. Consequently, a rectocele was doc-
umented in 93, an internal rectal prolapse in 77, and a muco-
haemorrhoidal prolapse in 35 patients. Out of the 77 patients
with an internal rectal prolapse, in 43 (56 %) patients was
documented an internal recto-rectal prolapse, and in 34 (44%)
patients an internal recto-anal prolapse.
Additionally to the clinical anorectal examinations and
proctoscopy, 97 patients had undergone diagnostic defecating
imaging in the local investigating centers, either by
defecography (68 %) or by MRI (29 %), which demonstrated
the presence of a rectocele in 80 % and an internal rectal
prolapse in 73 % of patients. Perineal descent was present in
19 % and a non-fixed enterocele in 14 % of patients. Only in
three patients, the additional defecating imaging
(defecography or MRI) was not performed based on the
decision of the local investigators in line with local policy.
Surgical findings
In the cohort, the mean hospitalization time was 4.36±2.75
(range, 1–12) days and the mean operative time was 43.8±
13.9 (range, 25–90)min. The mean weight of recorded spec-
imens was 37.8±25.3 g (range, 10–98 g). Concomitant sur-
geries were infrequently reported and comprised removal of
skin tag(s) in 5%, diagnostic laparoscopy in 5%, and excision
of anal polyp(s) in 1 % of patients.
Safety of the procedure
The safety analysis evaluated intra- and postoperative com-
plications of all patients entered in the study, regardless of
the completeness of other data or the length of follow-up.
In total, 3 % intraoperative and 8 % postoperative compli-
cations contributing to the overall TRANSTAR-related
morbidity rate of 11 % were recorded. Intraoperatively,
the three (3 %) staple line complications included a partial
dehiscence of the staple line in one (1 %) and spiraling of
the staple line in two patients (2 %). The partial dehiscence
of the staple line in one patient required immediate addi-
tional suturing with no further surgical re-intervention. The
spiraling of the staple line in two patients required conser-
vative treatment by observation and oral antibiotic medica-
tion with no further surgical treatment. Postoperatively,
eight complications (8 %) occurred, including bleeding
(5 %), urinary retention (2 %), and persistent pain (1 %).
Prolonged persistent pain in one patient required removal
of retained staples (agraphectomy). One patient with post-
operative bleeding received conservative treatment, and in
one patient the observed perirectal hematoma required sur-
gical re-intervention. In three patients, self-limiting rectal
bleeding was notified. Acute urinary retention occurred in
two patients (2 %) requiring interventions without anesthe-
sia. No major complications were documented and no
mortality occurred. A complete breakdown of the compli-
cations is given in Table 1.
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Effectiveness of the procedure
Study scoring systems Preoperatively and postoperatively ful-
ly completed questionnaires were analyzed at 12 months
follow-up, and the completeness of data collection varied
according to the scoring system used: KESS score 63 %,
ODS score 65.0 %, St. Mark’s incontinence score 65 %,
PAC-QoL score 65 %, EQ-5D score 64.0 %, and EQ-VAS
scale 64.0 %. Consequently, the overall scoring response rate
was in the very narrow range of 63–65 %.
Changes in the assessed study scoring systems’ mean and
median values between baseline and 12 months follow-up are
presented in Figs. 1 and 2.
Functional scores As the primary functional endpoint in this
study, the KESS constipation score was statistically signifi-
cantly improved at 12 months postoperatively. The median
score value improved from 18 [95 % CI: 15–22] to 6 [95 %
CI: 4–9]; (p<0.01), and the mean score value improved from
17.14 (SD 7.81); [95 % CI: 15.59–18.69] to 7.82 (SD 6.08);
[95 % CI: 6.29–9.35]; (p<0.01). Significant improvements
were recorded in all individual score items’ mean values at
12 months compared to baseline (Table 2). In accordance with
the KESS score validation report, a cut-off criterion of a
median KESS score ≥10 was used to differentiate constipated
patients from healthy individuals [20]. A total of 80 % of
patients presented a median KESS score change from ≥10 at
baseline to <10 at 12 months follow-up. The calculated odds
ratio showed that TRANSTAR statistically significantly re-
duced the risk of obstructive defecation at 12 months follow-
up, by more than ten times (OR=10.6; [95 % CI: 4.51–
24.92]), and presented in the Fig. 3. The number needed to
treat (NNT) for this benefit at 12 months follow-up was 2.
As the secondary functional endpoint in this study, the
ODS constipation score was statistically significantly im-
proved at 12 months postoperatively. The median score value
from 15 [95 % CI: 14–18] to 4 [95 % CI: 3–6] (p<0.01), and
the mean score value improved from 15.65 (SD 7.63); [95 %
CI: 14.13–17.16] to 5.52 (SD 4.86); [95 % CI: 4.31–6.72];
(p<0.01). Significant improvements were recorded in all in-
dividual score items’ mean values between baseline and
12 months postoperatively (Table 3).
St. Mark’s incontinence score improved numerically, but
nonsignificantly, with a median score value of 4 [95 % CI: 3–
7] at baseline, and of 3 [95%CI: 1–5] at 12months follow-up;
(p=n.s). Nonsignificant improvement was seen also in the
mean score value from 5.93 (SD 5.63); [95 % CI: 4.81–
7.04]; to 4.55 (SD 5.42); [95 % CI: 3.21–5.89]; (p=0.184) at
12 months postoperatively as compared with baseline.
Quality of life The disease-specific PAC-QoL score was sta-
tistically significantly improved at 12 months postoperatively.
The median disease-specific PAC-QoL score improved statis-
tically significantly from 2.10 [95 % CI: 1.85–2.30] to 0.86
[95 % CI: 0.65–1.11]; (p<0.01), and the mean score value
from 2.0 (SD 0.82); [95%CI: 1.83–2.16;] to 0.95 (SD 0.71);
Table 1 Combined reporting of complications (operative, peri- and








Staple line complications 3 3
Urinary retention 2 2
Persistent pain 1 1
Total 11 11
Fig. 1 Comparisons of study scores mean values at baseline and
12 months postoperatively. Statistically significant improvements were
observed in the KESS, ODS, and PAC-QoL scores at 12 months as
compared with baseline (*Wilcoxon signed ranks test and paired samples
t test, both P<0.01)
Fig. 2 Comparisons of study scores median values at baseline and
12 months postoperatively. Statistically significant improvements were
observed in the KESS, ODS, and PAC-QoL scores at 12 months as
compared with baseline (*Wilcoxon signed ranks test and paired samples
t test, both P<0.01)
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[95 % CI: 0.77–1.33]; (p<0.01). Significant improvements
were recorded in all four individual score domains (physical
discomfort, psychosocial discomfort, worries and concerns,
satisfaction) between baseline and 12 months follow-up
(Table 4).
The generic quality of life score EQ-5D improved numer-
ically, but nonsignificantly, with a median score value of 0.89
[95 % CI: 0.88–0.90] compared to 0.91 [95 % CI: 0.89–0.1.0]
at 12 months follow-up (p=n.s). A nonsignificant improve-
ment was seen also in the mean score values from 0.82 (SD
0.22); [95 % CI: 0.77–0.86]; to 0.86 (SD 0.24); [95 % CI:
0.79–0.92]; (p=0.184) at 12 months postoperatively as com-
pared with baseline.
The mean EQ-VAS score improved nonsignificantly from
54.26 (SD 26.45); [95 % CI: 49.07–59.61] to 56.30 (29.93);
[95 % CI: 48.82–63.77] (p=n.s), and the median score value
did not change between baseline and 12 months follow-up.
Fecal incontinence, urgency, and pain The postoperative risks
of fecal incontinence, defecatory urgency, and abdominal pain
were evaluated according to the specific questions derived
from the validated KESS and St. Mark’s scores assuming
the preoperative symptoms would remain unchanged in an
untreated control group. The postoperatively documented ad-
verse events were also taken into account.
Significant reductions in fecal incontinence (OR=0.30;
[95 % CI: 0.14–0.65]) and abdominal pain (OR=0.32;
[95 % CI: 0.15–0.67]) were observed at 12 months follow-
up. In contrast, a nonsignificant increase in the chance of
experiencing defecatory urgency (OR=1.15; [95 % CI:
0.55–2.40]) was noted at 12 months follow-up. Preoperative-
ly, 31 % of the enrolled patients experienced urgency symp-
toms. At 12 months follow-up, the urgency symptoms were
documented in 34 % of the surgically treated patients.
The odds ratios for fecal incontinence, urgency, and ab-
dominal pain at 1-year follow-up compared to baseline are
presented in Fig. 4.
Discussion
In this multicenter study, 22 individual surgeons assessed the
short-term safety, clinical effectiveness, and quality of life
outcomes after TRANSTAR performed in the real-world clin-
ical setting throughout Europe. The primary functional end-
point was the validated KESS constipation score, which im-
proved statistically significantly on all individual score items
between baseline and 12 months follow-up. Consequently, for
the vast majority of patients defecation difficulties improved
postoperatively, with 80% changing from constipated patients
to healthy individuals, according to the cut-off criterion from
Fig. 3 Odds ratio (OR) for ODS calculated from KESS score assuming
the preoperative symptoms would remain unchanged in an untreated
control group. TRANSTAR significantly reduce the risk of ODS by ten
times (OR=10.6) at 12months postoperatively, when a median of ≥10 for
KESS score was used as a cut-off criterion between constipated and non-
constipated groups
Table 2 The individual KESS score items mean values at baseline and 12 months postoperatively. Statistically significant improvements were observed
in all score items
KESS score items Baseline mean (SD) 12-months mean (SD) Difference of mean P value
Duration of constipation 1.95 (1.54) 1.40 (1.60) −0.55 p<0.01*
Laxative use 1.19 (1.12) 0.68 (0.86) −0.51 p<0.01*
Frequency of bowel movement 0.52 (0.72) 0.19 (0.47) −0.33 p<0.01*
Unsuccessful evacuatory events 1.29 (0.94) 0.40 (0.71) −0.89 p<0.01*
Feeling of incomplete evacuation 2.68 (1.23) 1.10 (1.20) −1.59 p<0.01*
Abdominal pain 1.54 (1.27) 0.76 (0.90) −0.78 p<0.01*
Bloating 1.10 (0.95) 0.73 (0.70) −0.37 p<0.01*
Enemas/digitation 1.87 (1.63) 0.40 (0.93) −1.48 p<0.01*
Time taken in lavatory/attempt 1.32 (0.78) 0.62 (0.69) −0.70 p<0.01*
Difficulty evacuating 2.86 (1.26) 1.00 (1.15) −1.86 p<0.01*
Stool consistency (without laxatives) 1.10 (0.93) 0.56 (0.67) −0.54 p<0.01*
Total score: mean (SD) 17.14 (7.81) 7.82 (6.08) −9.57 p<0.01*
*Wilcoxon signed ranks test and paired samples t test, both P<0.01
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the score validation report [20]. The risk assessment based on
the changes in the validated KESS score showed a highly
significant, more than ten times (OR=10.6) reduction in the
chance to experience symptoms of ODS at 12 months post-
operatively, and the number of patients needed to treat for
reaching this benefit was very low (NNT=2). This reflects the
real-world effectiveness of this transanal stapling procedure in
the treatment of ODS. To our knowledge, this is the first study
where the validated KESS score has been used as a primary
functional endpoint to assess the clinical effectiveness of
TRANSTAR.
Although not validated, the in the literature broadly report-
ed Longo’s ODS score was the secondary functional endpoint
in this cohort. It improved significantly, reflected by the
decrease in its overall mean and median values (−10.12 and
−11, respectively) at 12 months follow-up as compared to
baseline. In the literature, Wolff et al. [27] reported a signifi-
cant improvement in the ODS score after TRANSTAR,
expressed as a decrease (−11) in its median score value, at
6 months postoperatively. Savastano et al. [28] recently re-
ported a significant improvement in ODS score at 6 months
follow-up, expressed as a decrease (−10.8) in its mean score
value. Lenisa et al. [16] reported an even larger improvement
in ODS score at 1 year after TRANSTAR, expressed as a
decrease in mean score (−14.6). In the current study, the
observed mean and median ODS score improvements at
12 months follow-up appeared to be very similar to the sig-
nificant ODS changes reported in recently published trials.
This reinforces the clinical effectiveness of TRANSTAR as
assessed by the KESS score in this study.
The impressive improvements observed in the functional
constipation scores are supported by the significant improve-
ment in constipation-specific quality of life asmeasured by the
validated PAC-QoL score. The disease-specific PAC-QoL
score improved statistically significantly on all four quality
of life domains: patient’s satisfaction, physical discomfort,
psychosocial discomfort, and worries and concerns, reaching
statistical significance at 12 months follow-up as compared to
baseline. The generic quality of life score EQ-5D improved
numerically without reaching statistical significance, probably
due to its relatively high baseline value (0.82) in this cohort.
In the literature, Jane et al. reported significant improve-
ments in the validated quality of life instruments EQ-5D and
PAC-QoL at 12 months follow-up after STARR for ODS [15].
It has also been reported that patient quality of life significantly
improved after TRANSTAR, particularly on the mental com-
ponents of the FIQL and SF36 instruments [27]. In a recent
randomized controlled trial, Bocassanta et al. [29] reported that
Table 3 The individual ODS score items mean values at baseline and 12 months postoperatively. Statistically significant improvements were observed
in all score items
ODS score items Baseline mean (SD) 12-months mean (SD) Difference mean P value
Defecation frequency 1.08 (1.11) 0.34 (0.62) −0.74 p<0.01*
Intensive straining 1.51 (0.71) 0.55 (0.64) −0.95 p<0.01*
Time spent on defecation 1.52 (0.69) 0.75 (0.64) −0.77 p<0.01*
Feeling of incomplete defecation 2.20 (1.00) 0.91 (1.06) −1.29 p<0.01*
Pain 1.91 (1.18) 0.46 (0.79) −1.45 p<0.01*
Impact on daily activity 1.91 (2.16) 0.89 (1.42) −1.02 p<0.01*
Use of laxatives 2.05 (2.56) 1.09 (2.04) −0.95 p<0.01*
Use of enemas 1.26 (1.94) 0.28 (1.08) −0.98 p<0.01*
Digital assistance 2.20 (2.61) 0.25 (0.88) −1.95 p<0.01*
Total score: mean (SD) 15.65 (7.52) 5.52 (4.86) −10.12 p<0.01*
*Wilcoxon signed ranks test and paired samples t test, both P<0.01
Table 4 The individual PAC QoL score domains mean values at baseline and 12 months postoperatively. Statistically significant improvements were
observed in all score domains
PAC-QoL score domains Baseline mean (SD) 12-months mean (SD) Difference mean P value
Physical discomfort 1.92 (1.11) 0.84 (0.84) 1.04 p<0.01*
Psychosocial discomfort 1.37 (0.96) 0.63 (0.75) 0.75 p<0.01*
Worries and concerns 1.93 (0.94) 0.94 (0.78) 1.06 p<0.01*
Satisfaction 2.78 (0.95) 1.39 (0.95) 1.45 p<0.01*
Total score: mean (SD) 2.00 (0.82) 0.95 (0.71) −1.09 p<0.01*
*Wilcoxon signed ranks test and paired samples t test, both P<0.01
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the SF36 Health Survey score significantly improved after
STARR and TRANSTAR, and that TRANSTAR patients
showed a trend towards better satisfaction. The patient reported
outcomes in this study reinforce evidence from previous series
that transanal stapling procedures for ODS significantly im-
prove constipation-related patient quality of life.
Fecal incontinence has preoperatively been seen as a typ-
ical symptom of ODS, especially in patients with grade III
rectal intussusception and rectoceles [30], having negative
impact on patients’ quality of life. Moreover, fecal inconti-
nence also negatively affects well-being in patients with other
anorectal disorders [31–34]. However, in recently published
studies, it was observed that fecal incontinence usually im-
proved after transanal stapling procedures for ODS. In the
STARR Registry, Jane et al. [16] reported a significant im-
provement in the validated Cleveland Clinic Fecal Inconti-
nence score at 12-month follow-up as comparedwith baseline,
and this was mirrored by a significant improvement in patient-
reported symptoms of incontinence/soiling, captured as a
component of the symptom severity score [15]. Wolf et al.
[27] reported that all preoperatively incontinent patients in-
cluded in their trial were continent at 6 months after TRAN
STAR. Lenisa et al. [16] reported a 41 % incontinence cure
rate after TRANSTAR at 1-year follow-up as compared to
baseline. Isbert et al. [35] compared STARR and TRANSTAR
at 1-year follow-up, reporting that neither technique compro-
mised anal sphincter function, and that the postoperatively
gained ability to effectively evacuate the rectum may rather
help in reducing incontinence episodes. Additionally, it has
been observed that patients in whom fecal incontinence oc-
curred as a new symptom after TRANSTAR tended to be
those with a preexisting asymptomatic incontinence,
appearing after anatomic restoration [27, 35].
In this cohort study, the risk assessment (OR=0.30)
showed a significant reduction in the chance to experience
fecal incontinence at 12 months after TRANSTAR as com-
pared to baseline. The real-world data from this study rein-
forces the published evidence, showing that fecal incontinence
combined with an intact anal sphincter, observed preopera-
tively, may not be a contraindication for proposing transanal
surgery for ODS in itself [15, 16, 27, 35].
As a component of impaired continence, defecatory urgen-
cy has been seen as a common postoperative finding after
surgery using transanal stapling. Urge symptoms were report-
ed after a low anterior resection for rectal cancer and observed
up to 12 months postoperatively, without requiring any addi-
tional therapy [36]. In the treatment of ODS, defecatory ur-
gency was often recorded after STARR and after TRANSTAR
[15, 16, 37]. In the majority of patients, the urge symptoms
disappeared postoperatively without the need for any addi-
tional therapy, irrespective of whether it was observed as a
new onset of the symptom or it already persisted as a symptom
of the disease at baseline [16, 27, 35]. However, in the Euro-
pean STARR registry, 26.8 % of patients still complained of
urgency at 1-year follow-up [15]. Renzi et al. [17] and
Savastano et al. [28] reported an incidence of urge symptoms
of 17.2 and 18.7 %, respectively, at 6 months after TRAN
STAR. The reduction in the rectal ampula volume and mod-
ification of rectal sensitivity, as the natural consequences of
the TRANSTAR technique, appear to be the reason for the
increased risk of urge symptoms postoperatively [16, 27, 35].
In this study, the risk assessment showed a nonsignificant
increase (OR=1.15) in the chance to experience defecatory
urgency at 12 months follow-up as compared to baseline.
Consequently, St. Mark’s incontinence score, which includes
a specific urgency measure, was the only functional score in
this study that improved nonsignificantly at 12months follow-
up, probably due to a negative impact of urgency on the
overall score. However, patients should be informed about
the risk of urge symptoms, possibly for a prolonged period of
time after transanal stapling procedures for ODS.
In recent series, Wolf et al. [27] and Martelucci et al. [37]
reported TRANSTAR-related morbidity rates of 8 and 16 %,
respectively. Renzi et al. [17] reported up to 31 % early
complications and 24% late complications after TRANSTAR.
The safety analysis in this study showed a lower percentage
of intra- and postoperative complications recorded, contribut-
ing to the TRANSTAR-related morbidity rate of 11 %. Intra-
operatively, a lower proportion of 3 % complications such as a
partial dehiscence and spiraling of the staple line were record-
ed in this study, without any need for postoperative therapy.
Lenisa et al. reported moderate intraoperative difficulties with
TRANSTAR, including 5% partial dehiscence and 4% spiral-
ing of the staple line, concluding that the spiral resection of the
rectum during TRANSTAR may result from technical mis-
takes, such as inappropriate traction on the parachute stitches
at the top of the internal rectal prolapse, or from a larger
amount of the rectal wall incorporated into the jaw of the
Fig. 4 Odds ratio (OR) for fecal incontinence, pain, and urgency calcu-
lated from KESS score and St. Marks score assuming the preoperative
symptoms would remain unchanged in an untreated control group.
TRANSTAR significantly reduce the risk of fecal incontinence (OR=
0.30) and abdominal pain (OR=0.32) and nonsignificantly increase the
risk of urgency (OR=1.15) at 12 months postoperatively
Int J Colorectal Dis (2014) 29:611–622 619
device [16]. Accordingly, the immediate observation of the
staple line to detect possible staple line leakages has been
recommended [16].
Postoperatively, 5 % postoperative bleeding, 2 % urinary
retention, and 1 % persistent pain were recorded in this study.
The majority of patients with postoperative bleeding experi-
enced self-limiting bleeding episodes, and one patient needed
an additional surgical intervention for the revision of a
perirectal hematoma.
Postoperative bleeding has been presented in various series
in the literature as occurring in 1.5 to 7 % of patients after
TRANSTAR. Episodes are usually self-limiting, but if needed
they can be managed successfully with conservative treatment
or in rare cases by revision of the staple line [16, 35, 38].
According to recent series, the incidence of acute urinary
retention varies from 1.2 to 10.3 % and usually requires short-
term urinary catheterization [27, 37, 38], which is in accor-
dance with the two patients with urinary retention after TRAN
STAR in this study.
Moreover, it has been reported that some patients might
suffer from persistent anorectal pain after transanal stapling
procedures, caused by a proctitis due to retained staples [39].
The removal of the retained staples led to resolution of the
symptoms in previously published series [16, 27]. Similarly,
prolonged anorectal pain was observed postoperatively in one
patient in this study, and the surgical removal of the retained
staples contributed to its resolution.
However, abdominal pain can also be observed preopera-
tively, as part of the ODS symptoms [2]. In this study, the risk
assessment showed a significant reduction in the chance of
experiencing abdominal pain (OR=0.32) at 12 months
follow-up as compared to baseline. The data from this study
support previously published series concluding that retained
staples might occasionally be a cause of persistent pain after
TRANSTAR, but overall, the risk of postoperative abdominal
pain as a symptom of ODS seemed to be significantly
reduced.
No major or life-threatening complications after TRAN
STAR were recorded in this study, although they have been
reported in the literature. A rectal perforation was reported by
Schulte et al. [40], in which intraperitoneal occurring emphy-
sema was treated conservatively. A large hematoma in the
mesorectum extending towards both kidneys requiring a lap-
arotomy was reported by Gelos et al. after TRANSTAR [41].
Martelucci et al. [37] reported a rectal perforation and a
rectovaginal fistula after TRANSTAR, complications which
were also reported for the original STARR technique [37, 42].
Savastano et al. [28] reported a hemoperitoneum after TRAN
STAR, which was treated with synchronous colostomy and
subsequent recanalization.
Finally, if compared with the safety data from previously
published trials, the TRANSTAR-related morbidity profile
observed in this study appears to be acceptable.
Data incompleteness could be seen as a limitation of this
study because the questionnaires used for the 12-months anal-
ysis had a completeness range of 63–65 %, according to the
scoring system used. The reason for this is thought to be that the
majority of the study population consisted of elderly women,
and some felt embarrassed answering detailed questions
concerning their sexual functioning and defecation disorders.
Accordingly, some patients provided answers only for specific
chapters of the questionnaires, or they refused to fill out the
questionnaires preoperatively, and only did so after surgery.
However, this is not unexpected for an observational, real-
world study. For example, in the STARR registry, it was report-
ed that for the patients eligible for 12-month follow-up analysis,
the completeness of data collection varied from 41 to 64 %
according to the scoring system used [16]. Isbert et al. [35]
reported in their comparative observational trial that 58 % of
patients in the STARR group and 46% of patients in the TRAN
STAR group attended their follow-up assessments at 12 months.
Furthermore, it can be argued that the relatively short
follow-up of only 12 months postoperatively presents a limi-
tation of this study and that it needs to be proven that the
current functional results are sustainable in the longer term.
Indeed, outcomes from randomized clinical trials from 2 and
3 years after TRANSTAR have recently been published.
Renzi et al. [43] reported a longer maintenance of symptom
relief in patients who had undergone TRANSTAR compared
to those who underwent STARR at 2-year follow-up.
Bocassanta et al. [29] were able to demonstrate a significantly
lower incidence of fecal urgency and internal prolapse recur-
rence as two major benefits of TRANSTAR when compared
to STARR at 3-year follow-up. The authors concluded that the
prolapse recurrence rate was significantly lower in favor of
TRANSTAR compared to STARR, probably due to the larger
extent of rectal wall resection [29]. It can be concluded that the
impressive functional results achieved in the relatively artifi-
cial environment of these randomized clinical trials need to be
confirmed in broader surgical practice with larger patient
populations.
Conclusion
TRANSTAR facilitated a tailored, real circumferential full-
thickness rectal resection, performed in the real-world clinical
setting, without any major complications recorded. It led to
statistically significantly improved patient functional and
quality of life outcomes at 12 months postoperatively, as
measured by validated constipation-specific scoring systems
such as the KESS and PAC-QoL scores.
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